Report for Q3 2025
Filed with SSE · · 12 pages · Chinese
Kexing Biopharm Co., Ltd. on 6ix
Earlier from Kexing Biopharm
- Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
- Announcement on Adjusting the Remuneration of Independent Directors
- Announcement on Voluntary Disclosure on the Acceptance of Clinical Trial Registration Application for GB10 Injection
- Announcement on Voluntary Disclosure of Inclusion of Human Interferon α1b Inhalation Solution Being Included in the List of Drugs Granted Breakthrough Therapy Designation
- Kexing Biopharm's Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Registered with FDA DMF
Later from Kexing Biopharm
- Kexing Biopharm Showcases Global Strategy and Partnership Opportunities at CPHI Frankfurt 2025
- Announcement on Convening the Q3 2025 Performance Briefing
- Announcement on Cancellation of Special Settlement Accounts for Some Raised Fund Financial Products
- Shareholders' Inquiry Transfer Plan
- Indicative Announcement on Pricing for Shareholders' Inquiry-based Transfer
Follow Kexing Biopharm into a list and get an email when it puts out news.
Follow Kexing Biopharm